Market Overview

Cardurion Pharmaceuticals Appoints Rebecca Frey as Chief Operating Officer


, a biotechnology company focused on the development
of novel, next-generation therapeutics for the treatment of
cardiovascular diseases, today announced that it has expanded its
leadership team with the addition of chief operating officer, Rebecca V.
Frey, Pharm.D.

"The expansion of our leadership team will not only allow us to
streamline and optimize our operations, but further execute on our
strategic vision to deliver breakthrough treatments to target major
unmet needs in cardiovascular medicine," said Daniel Bloomfield, M.D.,
chief executive officer at Cardurion Pharmaceuticals. "Cardiovascular
disease is the leading cause of death in both men and women and
accounts for one-third of deaths worldwide.1,2 Rebecca's
strategic know-how and operational ingenuity will be critical for
Cardurion as we pursue our goal to transform the treatment of
cardiovascular disease."

Rebecca is a highly regarded leader who brings almost 20 years of
strategic and operational biotech experience to Cardurion
Pharmaceuticals. As chief operating officer, Rebecca will formulate
strategies and lead all aspects of operations to maximize value
creation. Prior to joining Cardurion Pharmaceuticals, Rebecca served as
executive vice president of operations at Prevail Therapeutics, where
she led clinical operations and early development planning. Prior to
that, Rebecca spent eleven years at Alexion Pharmaceuticals. During her
tenure, Rebecca held a wide range of leadership roles in development,
project management and manufacturing, including vice president of
operations and chief of staff to the CEO. Before Alexion, Rebecca spent
six years in clinical operations and medical affairs at Novartis
Pharmaceuticals. Rebecca earned her Doctor of Pharmacy from Northeastern
University and completed her post-doctoral clinical research fellowship
at Northeastern University and Tufts Medical Center. She is a 2017
graduate of the Women in Bio Boardroom Ready program.

"There exists a critical medical need for innovation to overcome the
burden of cardiovascular diseases, and I'm pleased to join a world-class
team of cardiologists with a deep understanding and desire to advance
treatments for patients who are living with heart failure," said Rebecca
Frey, chief operating officer at Cardurion Pharmaceuticals. "I am
excited to bring my capability and passion for disciplined execution to
Cardurion's management team, and I look forward to delivering on the
company's strategic priorities."

For additional information on Cardurion Pharmaceuticals' leadership
team, please visit the company's website:

About Cardurion Pharmaceuticals
Cardurion is a biotechnology
company with both clinical and preclinical programs focused on the
development of novel, next-generation therapeutics for the treatment of
heart failure and other cardiovascular diseases. Led by two
physician-scientists with extensive experience in cardiovascular
science, medicine and drug development, Cardurion's unique programs and
strongly collaborative environment enable the company to deliver
promising treatments that target major unmet needs. Cardurion has
facilities in Cambridge, Massachusetts and Shonan, Japan. For more
information, please visit the company's website at

Cardurion Pharmaceuticals' Forward Looking Statements
press release contains forward-looking statements, all of which are
qualified in their entirety by this cautionary statement. Any statements
contained herein that do not describe historical facts, are
forward-looking statements that are based on management's expectations
and are subject to certain factors, risks and uncertainties that may
cause actual results, outcomes, timing and performance to differ
materially from those expressed or implied by such statements. These
factors, risks and uncertainties include, but are not limited to: the
costs and uncertainties associated with our research efforts and other
discovery activities; the inherent uncertainties associated with the
conduct, timing and results of preclinical and clinical studies of our
product candidates; and the adequacy of our capital resources and
availability of additional funding. Except as otherwise noted, these
forward-looking statements speak only as of the date of this press
release, and we undertake no obligation to update or revise any of such
statements to reflect events or circumstances occurring after this press
release. We caution readers not to place undue reliance on the
forward-looking statements contained in this press release.

The safety and efficacy of the agent discussed herein are under
investigation and have not been established. There is no guarantee that
the agent will receive regulatory approval and become commercially
available for the uses being investigated. Information about
pharmaceutical products (including products currently in development)
which is included in this press release is not intended to constitute an
advertisement or medical advice.

Heart Association, Causes and Risks for Heart Failure (February 2018)

College of Cardiology, Cardiovascular disease causes one-third of deaths
worldwide (May 2017)

View Comments and Join the Discussion!